PUMA BIOTECHNOLOGY, INC. (PBYI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74587V1070
PUMA BIOTECHNOLOGY, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 228.37 m USD |
| Gross profit | 170.21 m USD |
| Operating income | 37.30 m USD |
| EBIT | 38.33 m USD |
| Net income | 31.11 m USD |
| Diluted EPS – continuing operations | 0.61 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
More stocks
- METHODE ELECTRONICS INC (MEI)
- Tokmanni Group Oyj (TOKMAN.HE)
- TRANSCONTINENTAL REALTY INVESTORS INC (TCI)
- Fidere Patrimonio SOCIMI SA (YFID.MC)
- NATHANS FAMOUS, INC. (NATH)
- AdvanSix Inc. (ASIX)
- BFF Bank SpA (BFF.MI)
- Lumosa Therapeutics Co. Ltd. (6535.TWO)
- Don Muang Tollway Public Company Limited (DMT.BK)
- Wanma Technology Co Ltd (300698.SZ)
- LAY-OUT Planning Consultants Co. Ltd. (300989.SZ)
- Isoenergy Ltd (ISO.TO)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.